1.
FGF-23 in bone biology
by Wesseling-Perry, Katherine
Pediatric nephrology (Berlin, West), 2009, Vol.25 (4), p.603-608
2.
Bone disease in pediatric chronic kidney disease
by Wesseling-Perry, Katherine
Pediatric nephrology (Berlin, West), 2012, Vol.28 (4), p.569-576
3.
Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3
by Wesseling-Perry, Katherine
The journal of clinical endocrinology and metabolism, 2017, Vol.102 (7), p.2340-2348
4.
The role of bone in CKD-mediated mineral and vascular disease
by Khouzam, Nadine M
Pediatric Nephrology, 2014, Vol.30 (9), p.1379-1388
5.
CKD-MBD after kidney transplantation
by Wesseling-Perry, Katherine
Pediatric nephrology (Berlin, West), 2011, Vol.26 (12), p.2143-2151
6.
Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients
by Hanudel, Mark R
Pediatric nephrology (Berlin, West), 2015, Vol.31 (4), p.661-669
7.
Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function
by Bacchetta, Justine
Pediatric nephrology (Berlin, West), 2012, Vol.27 (7), p.1131-1138
8.
FGF23 and mineral metabolism in the early post-renal transplantation period
by Wesseling-Perry, Katherine
Pediatric nephrology (Berlin, West), 2013, Vol.28 (11), p.2207-2215
9.
Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease
by Khouzam, Nadine
Pediatric nephrology (Berlin, West), 2017, Vol.34 (1), p.1-10
10.
Cortical and trabecular bone in pediatric end-stage kidney disease
by Carvalho, Catarina G
Pediatric nephrology (Berlin, West), 2014, Vol.30 (3), p.497-502
11.
Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically Active
by Shimada, Takashi
The journal of clinical endocrinology and metabolism, 2010, Vol.95 (2), p.578-585
12.
Relationship between Plasma Fibroblast Growth Factor-23 Concentration and Bone Mineralization in Children with Renal Failure on Peritoneal Dialysis
by Wesseling-Perry, Katherine
The journal of clinical endocrinology and metabolism, 2009, Vol.94 (2), p.511-517
13.
Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study
by Välimäki, Ville-Valtteri
The journal of clinical endocrinology and metabolism, 2017, Vol.102 (2), p.535-544
14.
Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease–mineral bone disorders (CKD-MBD) in children
by Wesseling-Perry, Katherine
Pediatric nephrology (Berlin, West), 2013, Vol.28 (4), p.617-625
15.
Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols
by Wesseling-Perry, Katherine
Pediatric nephrology (Berlin, West), 2009, Vol.24 (7), p.1355-1361
16.
Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease
by Fathallah-Shaykh, Sahar
Pediatric nephrology (Berlin, West), 2017, Vol.33 (2), p.325-333
17.
Lack of FGF23 Response to Acute Changes in Serum Calcium and PTH in Humans
by Wesseling-Perry, Katherine
The journal of clinical endocrinology and metabolism, 2014, Vol.99 (10), p.E1951-E1956
18.
The Calcemic Response to Continuous Parathyroid Hormone (PTH)(1-34) Infusion in End-Stage Kidney Disease Varies According to Bone Turnover: A Potential Role for PTH(7-84)
by Wesseling-Perry, Katherine
The journal of clinical endocrinology and metabolism, 2010, Vol.95 (6), p.2772-2780
19.
Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney diseaseâ[euro]"mineral bone disorders (CKD-MBD) in children
by Katherine Wesseling-Perry
Pediatric nephrology (Berlin, West), 2013, Vol.28 (4), p.617
20.
Response of different PTH assays to therapy with sevelamer or CaC[O.sub.3] and active vitamin D sterols
by Wesseling-Perry, Katherine
Pediatric nephrology (Berlin, West), 2009, Vol.24 (7), p.1355
